A caution on the use of murine hemophilia models for comparative immunogenicity studies of FVIII products with different protein compositions

Birgit M. Reipert; Axel Schoppmann; Hans Peter Schwarz

doi:10.1055/s-0037-1613416

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2003; 89(06): 1110-1112
DOI: 10.1055/s-0037-1613416

Letters to the Editor

Schattauer GmbH

A caution on the use of murine hemophilia models for comparative immunogenicity studies of FVIII products with different protein compositions

Birgit M. Reipert

,

Axel Schoppmann

,

Hans Peter Schwarz

Abstract

Full Text

References

References
1 Kreuz W, Auerswald G, Budde U, Lenk H, Klose H. Inhibitor incidence in previously untreated patients (PUBs) with hemophilia A and B - a prospective multicenter study of the GTH. 46th Annual Meeting of the German Society for Thrombosis and Haemostasis (GTH), February 2002, Erfurt, Germany. Ann Hematol 2002; 81 (Suppl. 01) Suppl A48
2 Behrmann M, Pasi J, Saint-Remy JMS, Kotitschke R, Kloft M. Von Willebrand Factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model. Thromb Haemost 2002; 88: 221-9.
3 Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian Jr HH. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 1995; 10: 119-21.
4 Muchitsch EM, Turecek PL, Zimmermann K. et al. Phenotypic expression of murine hemophilia (letter). Thromb Haemost 1999; 82: 1371-3.
5 Qian J, Borovok M, Bi L, Kazazian Jr HH, Hoyer LW. Inhibitor development and T cell response to human factor VIII in murine haemophilia A. Thromb Haemost 1999; 81: 240-4.
6 Reipert BM, Ahmad RU, Turecek PL, Schwarz HR. Characterization of antibodies induced by human factor VIII in a murine knockout model of hemophilia A. Thromb Haemost 2000; 84: 826-32.
7 Wu H, Reding M, Qian J, Okita DK, Parker E, Lollar P, Hoyer LW. Conti-Fine BM: Mechanism of the immune response to human factor VIII in murine hemophilia A. Thromb Haemost 2001; 85: 125 33
8 Sasgary M, Ahmad RU, Schwarz HP, Turecek PL and Reipert BM. Single cell analysis of factor VHI-specific T-cells in hemophilic mice after treatment with human factor VIII. Thromb Haemost 2002; 87: 266-72.
9 Hausl C, Maier E, Schwarz HP, Ahmad RU, Turecek PL, Reipert BM. Long-term persistence of anti-factor VIII antibody-secreting cells in hemophilic mice after treatment with human factor VIII. Thromb Haemost 2002; 87: 840-45.
10 Reipert BM, Schwarz HR. What can we learn from the immune response to human factor VIII in a mouse model of murine hemophilia A ? (letter) Thromb Haemost. 2002; 88: 374-5.
11 Qian J, Collins M, Sharpe AH, Hoyer LW. Prevention and treatment of factor VIII inhibitors in murine hemophilia A. Blood 2000; 95: 1324-9.
12 Qian J, Burkly LC, Smith EP, Ferrant JL. et al. Role of CD154 in the secondary immune response: the reduction of preexisting splenic germinal centers and anti-factor VIII inhibitor titers. Eur J Immunol 2000; 30: 2548-54.
13 Reipert BM, Sasgary M, Ahmad RU, Auer W, Turecek PL, Schwarz HP. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance Thromb Haemost. 2001; 86: 1345-52.
14 Rossi G, Sarkar J, Scandella D. Long-term induction of immune tolerance after blockade of CD40-CD40L interaction in a mouse model of hemophilia A. Blood 2001; 97: 2750-7.
15 Schwaab R, Brackmann HH, Meyer C. et al. Haemophilia A: Mutation type determines risk of inhibitor formation. Thromb Haemost 1995; 74: 1402-6.
16 Tuddenham EGD, McVey JH. The genetic basis of inhibitor development in hemophilia A. Haemophilia 1998; 4: 543-5.
17 Fakharzadeh SS, Kazazian HH. Correlation between factor VIII genotype and inhibitor development in hemophilia A. Sem Thromb Hemost 2000; 26: 167-71.
18 Adler FL. Competition of antigens. Progr Allergy 1964; 8: 41-57.
19 Taussig MJ. Antigenic competition. Curr Top Microbiol Immunol 1973; 60: 125-74.
20 Pross HF, Eidinger D. Antigenic competition: a review of nonspecific antigen-induced suppression. Adv Immunol 1974; 18: 133-68.
21 Hunt JD, Jackson DC, Wood PR, Stewart DJ, Brown LE. Immunological parameters associated with antigenic competition in a multivalent footrot vaccine. Vaccine 1995; 17: 1649-57.
22 Babbitt BP, Matsueda G, Haber E, Unanue ER, Allen PM. Antigenic competition at the level of peptide-Ia binding. PNAS 1986; 83: 4509-13.
23 Adorini L, Nagy ZA. Peptide competition for antigen presentation. Immunol Today 1990; 11: 21-4.
24 Johansson BE, Moran TM, Kilbourne ED. Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between influenza A virus and surface glycoproteins. PNAS 1997; 84: 6869-73.
25 Smith AL, Wikstrom ME, Fazekas de St. Groth B. Visualizing T cell competition for peptide/MHC complexes: a specific mechanism to minimize the effect of precursor frequency. Immunity 2000; 13: 783-94.
26 Kawasaki T, Kaida T, Arnout J, Vermylen J, Holyaerts MF. A new animal model of thrombophilia confirms that high plasma factor VIII levels are thrombogenic. Thromb Haemost 1999; 81: 306-11.